A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Clinical trial NCT01268839 · COMPLETED
Trial details
- NCT number
- NCT01268839
- Sponsor
- Tibotec, Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-01-01
- Primary completion
- 2010-05-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.